SYS-CON MEDIA Authors: Doug Masi, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

Vital Therapies, Inc. Enrolls First Subject From European Site in VTI-208

SAN DIEGO, CA -- (Marketwired) -- 02/18/14 -- Vital Therapies, Inc., a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure, today announced that it has enrolled the first subject from an European clinical trial site in VTI-208, a Phase 3 randomized, controlled clinical trial in 200 subjects with alcohol-induced liver decompensation, or AILD. The subject was enrolled last month at the Queen Elizabeth Medical Centre in Birmingham, United Kingdom.

As of today, 73 subjects have been enrolled in VTI-208 with 37 clinical sites in the United States, Europe and Australia open for enrollment.

About Vital Therapies, Inc.

Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure. The company's lead product-candidate, ELAD, is an extracorporeal bio-artificial liver currently in Phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.

This press release may contain forward-looking statements, including but not limited to statements regarding Vital Therapies, Inc.'s current and future clinical studies. These statements relate to future events and are subject to risks, uncertainties and assumptions. These statements are only predictions based on the company's current expectations and projections about future events. You should not place undue reliance on these statements. Many factors or events may cause the company's actual results to differ materially from any forward-looking statement. Vital Therapies, Inc. does not undertake to update any forward-looking statements. In addition, note historic clinical trial enrollment rates are not necessarily indicative of future enrollment rates. Subject enrollment is affected by numerous factors, many of which fall outside the company's control.

CONTACT:
Terry Winters
Co-Chairman & Chief Executive Officer
Duane Nash
Chief Business Officer
Vital Therapies, Inc.
858-673-6840

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.